See the DrugPatentWatch profile for cosentyx

When considering the use of Cosentyx (secukinumab) in conjunction with other vaccines, it is essential to consult with a healthcare professional. However, based on the available information, there are no specific vaccines that are absolutely contraindicated with Cosentyx. Nevertheless, it is crucial to consider the impact of Cosentyx on the immune system and the potential implications for vaccine efficacy.

Cosentyx is a human monoclonal antibody that selectively binds to interleukin-17A (IL-17A) and inhibits its interaction with the IL-17 receptor. By neutralizing IL-17A, Cosentyx helps reduce inflammation and symptoms associated with various conditions such as plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis [1]. Since Cosentyx impacts the immune system, it may affect the body's response to vaccines.

According to the prescribing information for Cosentyx, "the use of live vaccines during or following treatment with Cosentyx is not recommended" [2]. This recommendation is based on the potential impact of Cosentyx on the immune system, which may affect the patient's ability to mount an adequate immune response to live vaccines.

Inactivated or non-live vaccines, on the other hand, can generally be administered before, during, or after Cosentyx treatment, provided that the patient's clinical situation allows [2]. However, it is essential to note that the efficacy of these vaccines might be reduced due to the immunosuppressive effects of Cosentyx [3].

In summary, while there are no specific vaccines that are absolutely contraindicated with Cosentyx, it is crucial to consider the potential impact of Cosentyx on the immune system and vaccine efficacy. Live vaccines should be avoided during Cosentyx treatment, while inactivated or non-live vaccines can generally be administered with caution. Consult with a healthcare professional for personalized advice.

Sources:
[1] Novartis Pharmaceuticals Corporation. Cosentyx (secukinumab) [Prescribing Information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; 2021. Available from: <https://www.pharma.us.novartis.com/sites/www.pharma.us.novartis.com/files/cosentyx.pdf>.
[2] DrugPatentWatch. Secukinumab (Cosentyx). Available from: <https://www.drugpatentwatch.com/drugs/secukinumab>.
[3] Centers for Disease Control and Prevention. Vaccine recommendations and guidelines of the ACIP. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2011;60(RR-2):1-100. doi: 10.15585/mmwr.rr6002a1. Available from: <https://www.cdc.gov/mmwr/pdf/rr/rr6002.pdf>.